Published in Arch Neurol on October 01, 2004
Task-specific dystonias: a review. Ann N Y Acad Sci (2008) 1.54
A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry (2006) 1.13
Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort. Parkinsonism Relat Disord (2013) 1.05
Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y) (2013) 1.02
Clustering of dystonia in some pedigrees with autosomal dominant essential tremor suggests the existence of a distinct subtype of essential tremor. BMC Neurol (2010) 1.01
Genetic and clinical features of primary torsion dystonia. Neurobiol Dis (2010) 1.00
Accuracy of family history information on epilepsy and other seizure disorders. Neurology (2011) 0.99
Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology (2013) 0.87
Phenotypic overlap in familial and sporadic primary adult-onset extracranial dystonia. J Neurol (2012) 0.81
Advances in the genetics of primary torsion dystonia. F1000 Biol Rep (2010) 0.80
Allelic Imbalance in TOR1A mRNA Expression in Manifesting and Non-Manifesting Carriers of the GAG-Deletion. J Nucleic Acids (2012) 0.75
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol (2007) 3.87
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
A comparative study of cortical responses evoked by transcutaneous electrical vs CO(2) laser stimulation. Clin Neurophysiol (2011) 2.83
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist (2008) 2.22
Sensorimotor integration in movement disorders. Mov Disord (2003) 2.09
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol (2007) 2.08
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol (2008) 1.99
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Consensus: Motor cortex plasticity protocols. Brain Stimul (2008) 1.86
Do primary adult-onset focal dystonias share aetiological factors? Brain (2007) 1.83
Epidemiology of primary dystonia. Lancet Neurol (2004) 1.71
Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord (2010) 1.66
A comparative study of primary and secondary hemifacial spasm. Arch Neurol (2006) 1.65
The focal dystonias: current views and challenges for future research. Mov Disord (2013) 1.62
Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci (2007) 1.61
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet (2006) 1.56
Serum levels of N-acetyl-aspartate in migraine and tension-type headache. J Headache Pain (2012) 1.54
Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family. Can J Neurol Sci (2003) 1.40
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.27
Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. Epilepsia (2007) 1.22
Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol (2013) 1.17
Correlation between cortical plasticity, motor learning and BDNF genotype in healthy subjects. Exp Brain Res (2011) 1.16
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Age-related disability in multiple sclerosis. Ann Neurol (2002) 1.12
Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol (2011) 1.08
Rate of MMSE score change in Alzheimer's disease: influence of education and vascular risk factors. Clin Neurol Neurosurg (2008) 1.07
Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? Brain (2006) 1.07
Cortical excitability is abnormal in patients with the "fixed dystonia" syndrome. Mov Disord (2008) 1.06
The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia. Mov Disord (2010) 1.05
Disassembly of shank and homer synaptic clusters is driven by soluble beta-amyloid(1-40) through divergent NMDAR-dependent signalling pathways. PLoS One (2009) 1.05
Predictors of long survival in amyotrophic lateral sclerosis: a population-based study. J Neurol Sci (2007) 1.05
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol (2003) 1.04
Phasic voluntary movements reverse the aftereffects of subsequent theta-burst stimulation in humans. J Neurophysiol (2008) 1.03
Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm. Mov Disord (2007) 1.03
The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosom Res (2009) 1.03
Temporal discrimination in patients with dystonia and tremor and patients with essential tremor. Neurology (2012) 1.02
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer (2014) 1.02
Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci (2006) 1.01
Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes (2006) 1.01
Attention influences the excitability of cortical motor areas in healthy humans. Exp Brain Res (2007) 1.01
Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol (2002) 1.01
Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord (2005) 1.00
Mirror movements in patients with Parkinson's disease. Mov Disord (2008) 1.00
Tremor in primary adult-onset dystonia: prevalence and associated clinical features. J Neurol Neurosurg Psychiatry (2012) 0.99
Impairment of individual finger movements in Parkinson's disease. Mov Disord (2003) 0.99
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol (2012) 0.99
Voluntary, spontaneous, and reflex blinking in Parkinson's disease. Mov Disord (2008) 0.98
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler (2006) 0.97
Central effects of botulinum toxin type A: evidence and supposition. Mov Disord (2004) 0.97
The neurobiology of falls. Neurol Sci (2012) 0.96
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis (2012) 0.96
Facial bradykinesia. J Neurol Neurosurg Psychiatry (2012) 0.96
Lack of habituation of nociceptive evoked responses and pain sensitivity during migraine attack. Clin Neurophysiol (2005) 0.96
Repetitive magnetic stimulation of cortical motor areas in Parkinson's disease: implications for the pathophysiology of cortical function. Mov Disord (2002) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Defining the epsilon-sarcoglycan (SGCE) gene phenotypic signature in myoclonus-dystonia: a reappraisal of genetic testing criteria. Mov Disord (2013) 0.96
Novel Italian family supports clinical and genetic heterogeneity of primary adult-onset torsion dystonia. Mov Disord (2002) 0.96
Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res (2012) 0.95
Novel parkin mutations detected in patients with early-onset Parkinson's disease. Mov Disord (2005) 0.94
Clinical features of headache patients with fibromyalgia comorbidity. J Headache Pain (2011) 0.94
Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry (2011) 0.94
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer (2011) 0.94
Subthalamic nucleus stimulation and somatosensory temporal discrimination in Parkinson's disease. Brain (2010) 0.94
Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord (2006) 0.93
Cortical gray matter changes in primary blepharospasm: a voxel-based morphometry study. Mov Disord (2011) 0.93
Epidemiology of primary blepharospasm. Mov Disord (2002) 0.93
Task-dependent modulation of excitatory and inhibitory functions within the human primary motor cortex. Exp Brain Res (2003) 0.92
Theta-burst stimulation-induced plasticity over primary somatosensory cortex changes somatosensory temporal discrimination in healthy humans. PLoS One (2012) 0.92
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord (2005) 0.92
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler (2003) 0.92
Glatiramer acetate in multiple sclerosis: a review. CNS Drug Rev (2007) 0.92
Effects of intermittent theta-burst stimulation on practice-related changes in fast finger movements in healthy subjects. Eur J Neurosci (2008) 0.91
Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. Curr Neurovasc Res (2012) 0.91
Task-specific impairment of motor cortical excitation and inhibition in patients with writer's cramp. Neurosci Lett (2005) 0.91
Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov Disord (2010) 0.90
Primary blepharospasm: diagnosis and management. Drugs (2004) 0.90
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol (2009) 0.90